BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for...
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization...
TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond...
Berkeley Heights, New Jersey--(Newsfile Corp. - November 24, 2025) - Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization...
Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reported by year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended...
Highly experienced biopharma financial officer joins leadership team CFO hire bolsters Kalaris’ leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study...
PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization...
Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection...
Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and preliminary efficacy in nAMD patients receiving up to four initial monthly doses of TH103 Phase 1b/2 study...
Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular...